Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 5, 2025
Reporting Period: Event date March 5, 2025
The filing addresses the resolution of a listing compliance matter with The Nasdaq Stock Market LLC regarding the Company's continued listing on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status.
Material Changes
- Compliance Resolution: The Company received formal notice from Nasdaq evidencing compliance with all applicable criteria for continued listing, specifically the minimum stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)).
- Closure of Matter: The previously disclosed listing compliance matter has been officially closed.
Outlook, Risks, and Management Commentary
- Panel Monitor Status: The Company remains subject to a "Panel Monitor" for one year from the date of the notice, through February 26, 2026.
- Future Compliance Risk: If the Company fails to satisfy the Equity Rule during the Panel Monitor period, it will not be permitted to submit a compliance plan. Instead, it must request a hearing before the Nasdaq Hearings Panel to address the deficiency.
- Management Action: A press release announcing the compliance determination was issued on March 5, 2025, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the Company's current stockholders' equity to ensure ongoing compliance with Nasdaq Listing Rule 5550(b)(1).
- Monitor the Company's status through the Panel Monitor period ending February 26, 2026.
- Review the attached press release (Exhibit 99.1) for additional details on the compliance determination.
- Confirm that no further listing deficiencies have been disclosed in subsequent filings.